What is VetDC?
VetDC operates at the intersection of biotechnology and veterinary medicine, specializing in the development of novel cancer treatments for pets. The company is dedicated to improving the quality of life for animal companions through the creation of breakthrough therapies, such as TANOVEA-CA1. By applying rigorous, evidence-based methodologies typically reserved for human clinical trials, VetDC addresses critical unmet needs in veterinary oncology. Their market position is defined by a unique focus on high-efficacy treatments that provide veterinarians and pet owners with sophisticated tools to manage and treat life-threatening malignancies in domestic animals.
How much funding has VetDC raised?
VetDC has raised a total of $5.7M across 5 funding rounds:
Private Equity
$1.5M
Private Equity
$1.3M
Grant
$250K
Private Equity
$587K
Private Equity
$2.1M
Private Equity (2012): $1.5M, investors not publicly disclosed
Private Equity (2013): $1.3M, investors not publicly disclosed
Grant (2013): $250K supported by Colorado Office of Economic Development & International Trade
Private Equity (2014): $587K, investors not publicly disclosed
Private Equity (2015): $2.1M, investors not publicly disclosed
Key Investors in VetDC
Colorado Office of Economic Development & International Trade
The Colorado Office of Economic Development and International Trade (OEDIT) promotes economic growth and long-term job creation by supporting small businesses and encouraging expansion throughout Colorado. They provide resources for entrepreneurs, including low-cost training and no-cost advising, aimed at ensuring that small businesses thrive across the state.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for VetDC?
With the recent influx of capital, VetDC is well-positioned to accelerate its research and development initiatives. The strategic focus will likely shift toward expanding the clinical application of its existing therapeutic portfolio and exploring new frontiers in veterinary oncology. As the company scales, it will continue to leverage its expertise in drug development to enhance its competitive advantage in the animal health market. Future growth will be driven by the successful commercialization of its pipeline, further cementing its reputation as a pioneer in the veterinary biotech space and ensuring that innovative, life-saving treatments remain accessible to the veterinary community.
See full VetDC company page
